ARS Pharmaceuticals, Inc. — Director's Dealing 2023

Aug 31, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2023-08-29

Reporting Person: RA CAPITAL MANAGEMENT, L.P. (Director)
Reporting Person: RA Capital Healthcare Fund LP (Director)
Reporting Person: RA Capital Nexus Fund II, L.P. (Director)
Reporting Person: Kolchinsky Peter (Director)
Reporting Person: Shah Rajeev M. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-29	Common Stock	P	3750000	$6.20	Acquired	5856774	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	902904	Indirect

Footnotes

F1: On August 29, 2023, the Fund (as defined in footnote (2)) entered into a contract to purchase the shares from a third-party seller in a privately negotiated transaction.

F2: These shares are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3: These shares are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").

F4: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.